“Managing hundreds of products across multiple species requires a different approach to network strategy than human pharma,” explains Bernhard Boehm, Head of External Manufacturing for Animal Health at Boehringer Ingelheim. Bernhard Boehm leads external manufacturing for animal health as VP
“We’ve combined these two solid legacies into a new, agile CDMO with a unique focus on high-value small and medium-scale production,” says Bruce Vielle, CEO of the newly formed Meribel Pharma Solutions. Bruce Vielle, an experienced industrial business leader with
“Trust is what your customers need most. They take a great risk when they sign up with you to make their product. They need access within your organization to feel confident you’ll get things done the way they want.” –
“What we’re witnessing is the rapid dismantling of the US research infrastructure… It’s also an opportunity for us here in Europe to step up” Dr. Oliver Schacht, Managing Director of Life Science Nord Dr. Oliver Schacht, Managing Director of Life
“Being in a CDMO business, we don’t just provide a service, but it’s more about building a partnership with our customers.” – Payal Gandhi In the latest PharmarSource podcast episode, Payal Gandhi, Management Executive – Business Growth at Blue Jet
“Europe has roughly double the population of the United States but lower pricing, so it’s a balancing act between how much volume can you get and how little price discount you give.” – Joshi Venugopal Joshi Venugopal, Head of Region
“Being unique or special in something is crucial, a key factor in order to gain success in this field.” – Angela Molaschi Angela Molaschi, Chief Commercial Officer at Fisiopharma, and Nicola Cadei, General Manager, bring decades of pharmaceutical industry experience
“Digital transformation is not about technology deployment. It’s about a new way of doing business that allows you to make jumps which were not possible before, like reducing launch time from 70 weeks to 7 weeks.” – Dr. Franziskus Kath
“Cell and gene therapy is in a winter period. We just need to hold our breath and adapt ourselves to the weather,” observed Miguel Forte, President of ISCT & CEO of Kiji Therapeutics. Miguel Forte chaired the Advanced Therapies UK
“What we’re witnessing is a fundamental shift from globalized to decentralized pharma supply chains, yet many companies are hesitant to make the bold capacity investments needed despite recognizing the risks.” – Stephan Fath, Director at Roland Berger Stephan Fath is
Stay ahead of trends and best practices 
Exclusive downloads and podcasts 
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
